University of Western Australia life sciences spin-out iCeutica has its lead drug approved by the FDA.

Duke spin-out Aerie Pharmaceuticals sets its pre-IPO price range.

Novartis Pharmaceuticals signs deal worth a possible $300m to acquire the lead drug asset of Sideris Pharmaceuticals for the treatment of transfusion-related iron overload; concurrently, Sideris raises $32m series A funding.

CYP Design, a spin-out of De Montfort University, receives unspecified seed fund from investment firm Mercia.

University venture fund Osage University Partners backs Sideris Pharmaceuticals in $32m series A.

Natural products company ChromaDex receives an undisclosed amount of equity financing from DSM Venturing.

Japanese pharmaceutical company Astellas Pharma joins $45m series A funding for Mitokyne, a US biotech focused on discovering drugs to treat mitochondria-related diseases, as well as signing R&D collaboration agreement with option to acquire.

Connecticut Innovations leads $1.8m series B in Yale-linked Precipio.

Biotechnology company Biodesy raises $15m series A funding led by 5AM Ventures and including Pfizer Venture Investments and Roche Venture Fund, to develop and commercialize its technology for real-time measurement of changes in protein structure.

Fusion Antibodies and Isca Diagnostics announce collaboration on antibodies.